THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM ANY PART OF AN OFFER TO SELL OR ISSUE, OR A SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN THE UNITED STATES, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NO PUBLIC OFFERING OF THE FUNDRAISE SHARES IS BEING MADE IN ANY SUCH JURISDICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF SUCH JURISDICTIONS.

THIS ANNOUNCEMENT IS NOT FOR PUBLIC RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION NO. 596/2014 ("MAR") AS IN FORCE IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

4 August 2022

Alkemy Capital Investments Plc

Oversubscribed Placing to raise £1,200,000 and Directors Purchase of Shares

Alkemy Capital Investments plc ("Alkemy") (LSE: ALK) and its wholly owned subsidiary Tees Valley Lithium Ltd ("TVL") are pleased to announce the following corporate update.

Highlights:

·    £1,200,000 new funds, before expenses, raised by Alkemy from new and existing shareholders through a placing of 1,200,000 new ordinary shares at £1 per share.

·    £178,000 of these new shares are being subscribed for by Directors, showing strong support.

Fundraise and Director Purchase of Shares

Alkemy is pleased to announce that it has raised £1,200,000 in an oversubscribed placing of 1,200,000 new ordinary shares at a placing price of  £1 per share.

This includes cash subscriptions of £178,000 from the directors, including Paul Atherley (£78,000), Sam Quinn (£75,000) and Helen Pein (£25,000).

The net proceeds will be used to further fastrack the development of TVL's lithium hydroxide processing faclility in Teesside, UK and for general working capital purposes.

Following the placing, the directors will have the following beneficial shareholdings in the Company:

An application will be made for 1,200,000 Ordinary Shares to be admitted to the official list (Standard Segment) and to trading on the Main Market of the London Stock Exchange ("Admission") and Admission is expected to occur at 8.00 a.m. on 9 August 2022.

In accordance with the FCA's Disclosure Guidance and Transparency Rules, the Company confirms that following Admission, the Company's enlarged issued ordinary share capital will comprise 7,199,999 Ordinary Shares each with a right to vote and with no shares held in treasury. Therefore, following Admission, the above figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the FCA's Disclosure Guidance and Transparency Rules.

Grant of Share Options

The Company also announces the proposed grant of 590,000 share options at £1 per share, for a period of 5 years, to further align Directors and senior management with shareholders.   A further announcement will be made once the options have been granted. 

Alkemy and TVL Director, Sam Quinn, commented:

"We are grateful to all the existing and new shareholders who have contributed to this fundraise, which will help enable the further fast-tracked development of TVL's lithium hydroxide processing facility in Teesside, UK. Funds will be used to commence and advance FEED and to complete the planning process. We appreciate the ongoing support from all stakeholders and look forward to a successful year ahead as we move to establish the UK's first major independent and sustainable lithium hydroxide producer at the Wilton International Chemicals Park in Teesside, UK".

Further information

For further information, please visit the Company's website: www.alkemycapital.co.uk or www.teesvalleylithium.co.uk

-Ends-

NOTES TO EDITORS

Alkemy is seeking to develop, construct and operate the world's leading independent and sustainable lithium hydroxide production facility.

Alkemy, through its wholly-owned subsidiary Tees Valley Lithium, has secured exclusivity to negotiate an option to lease over a 9.6ha brownfields site at the Wilton International Chemicals Park located in Teesside, a major UK Freeport.

Alkemy has completed a Class 4 Feasibility Study for its proposed lithium hydroxide facility to process feedstock imported from various sources to produce 96,000 tonnes of premium, low-carbon lithium hydroxide annually, representing around 15% of Europe's projected demand.

Forward Looking Statements

This news release contains forward‐looking information. The statements are based on reasonable assumptions and expectations of management and Alkemy provides no assurance that actual events will meet management's expectations. In certain cases, forward‐looking information may be identified by such terms as "anticipates", "believes", "could", "estimates", "expects", "may", "shall", "will", or "would". Although Alkemy believes the expectations expressed in such forward‐looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those projected. In addition, factors that could cause actual events to differ materially from the forward-looking information stated herein include any factors which affect decisions as to how to develop the project, process the materials and exercise the option in respect of the lease, which may include changes in market conditions, changes in metal prices, general economic and political conditions, environmental risks, and community and non-governmental actions. Such factors will also affect whether Alkemy will ultimately receive the benefits anticipated pursuant to relevant agreements. This list is not exhaustive of the factors that may affect any of the forward‐looking statements. These and other factors should be considered carefully and readers should not place undue reliance on forward-looking information.

The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to the transaction listed above is set out below.